Syncona traces its origins to BACIT, a publicly listed investment company on the London Stock Exchange that used a fund-of-funds portfolio to seek shareholder returns while investing in oncology research and making charitable donations. BACIT combined with Syncona Partners and was renamed Syncona, shifting the combined business toward life-science investment.
synconaltd.comCrawled Oct 22, 2026
Syncona has one of the largest and highest quality gene therapy platforms globally with the potential to deliver dramatic efficacy across genetic diseases.
A portfolio of life science companies diversified across a range of therapeutic areas and different stages of the development cycle.
Gene therapy replaces defective genes with functional ones to treat or prevent genetic disorders, offering potential long-term benefits.
Syncona invests in and partners with healthcare companies to build scalable businesses, aiming for global leadership and strong returns for shareholders.
The page shares news and insights about Syncona and its portfolio companies.
The recommendation is for Axumin use in Positron Emission Tomography (PET) imaging to detect recurrence of prostate cancer in adult men with a suspected recurrence based on elevated blood prostate specific antigen (PSA) levels after primary curative treatment. The CHMP’s positive opinion will now be reviewed by the European Commission. If approved, Axumin will be the first and only PET imaging agent indicated for use in men with suspected recurrent prostate cancer in all European Union member st
Nightstar is enrolling patients in a Phase I/II clinical trial for X-Linked Retinitis Pigmentosa (XLRP), the first of its kind worldwide.
Chris is the Chief Executive Officer and Chief Investment Officer of Syncona Investment Management Ltd.
Edward Hodgkin is a Managing Partner of Syncona Investment Management Ltd.
Elisa is a Managing Partner of Syncona Investment Management Limited.
Melanie Gee is Chair and joined the Board in June 2019. Melanie has over 30 years financial advisory experience in executive positions in investment banking, advising clients across a broad range of sectors and geographies. Melanie also has extensive Non-Executive experience, having spent eight years in Non-Executive Director roles for three FTSE100 and 250 companies where she has served on numerous committees.
Syncona aims to build a diversified portfolio of 15–20 globally leading healthcare businesses over a decade.
Syncona was co-founded in 2012 by the Wellcome Trust and has since added 25companies to its portfolio investing over £1.2 billion in attractive therapeutic areas.
Syncona aligns its sustainability reporting with a number of well-known frameworks.
Syncona focuses on sustainable business practices, responsible investment, and supporting portfolio companies in addressing high unmet medical needs.
The page provides contact details based on the type of inquiry.
Syncona is a FTSE250 company focused on founding, building and funding healthcare companies to deliver transformational treatments to patients in areas of high unmet need.